Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Buyout already started by, "a dedicated healthcare institutional investor".
Still time to get in on the ground floor, but this thing could go viral after today's conference call.
Conference Call & Webcast
Tuesday, May 12, 2015 @ 8:30am Eastern Time/5:30am Pacific Time Domestic: 888-299-7209 International: 719-325-2448 Passcode: 1277819 Webcast: http://www.nanosphere.us/investors - See more at: http://globenewswire.com/news-release/2015/05/11/734749/10133869/en/Nanosphere-Announces-Record-Q1-2015-Results-New-and-Expanded-Debt-Facility-4-4-Million-at-the-Market-Registered-Direct-Offering-and-Next-Generation-Verigene-System-Progress.html#sthash.eMIpB3YX.dpuf
Nanosphere Q1 Revenues Jump 41 Percent
May 11, 2015 | a GenomeWeb staff reporter
NEW YORK (GenomeWeb) – Nanosphere today announced after the close of the market that its first quarter revenues rose 41 percent on sales of its Verigene Gram Positive and Gram Negative Blood Culture Tests.
The firm also said that it has entered into a definitive agreement with an institutional investor in a registered direct offering of $4.4 million and entered into a new $30 million debt facility with NSPH Funding.
For the three months ended March 31, 2015, the Northbrook, Illinois-based molecular diagnostics company said that revenues increased to $4.6 million from $3.3 million a year ago, beating the average Wall Street expectation of $4.5 million.
Sales of the blood culture tests in the quarter more than doubled year over year compared to Q1 2014, the firm said in a statement.
"We are pleased to report continued adoption of our Verigene system and its expanding menu though our US customer base. In addition, we have made significant progress on our next-generation Verigene system," Nanosphere President and CEO Michael McGarrity said in a statement.
Nanosphere also entered into a registered direct offering fo $4.4 million of convertible preferred stock, convertible into more than 1.1 million shares of common stock at a conversion price of $3.77, and issued warrants for more than 1.1 million shares of common stock at an exercise price of $3.65 per share, exercisable for five years and six months from the closing date. The firm said it expects to close the offering on or about May 14. H.C. Wainwright & Co. acted as the exclusive placement agent of the offering.
Also, on May 7, the firm entered into a commitment letter that provides for a new $30 million debt facility with NSPH Funding. The firm said it expects to draw down $20 million from the facility at an initial closing on or before May 22 and terminate its existing debt facility with Silicon Valley Bank and Oxford Finance.
The firm said it intends to use the proceeds of the offering and the debt facility for general corporate purposes and working capital.
The firm's net loss in the quarter was $7.5 million, or $1.29 per share, compared to a net loss of $10.0 million, or $2.60 per share, a year ago, beating the consensus Wall Street estimate of a net loss per share of $1.79.
Nanosphere's R&D spending dropped 30 percent to $3.6 million from $5.2 million during the first quarter of 2014, due to reduced staffing and clinical trial expenses. SG&A costs fell 7 percent to $5.2 million from $5.6 million.
Nanosphere ended the quarter with $14.2 million in cash and cash equivalents.
"The remainder of 2015 will be spent advancing the significant progress made to date and preparing for clinical trials targeted to commence by year-end," McGarrity said.
Something big is happening!
Sorry, can't share any details at this point. Stay tuned.
Been buying on the dips and selling on the bounces. Nice action this week. Completed my 2nd round-trip!!!
MLV & Co. Reaffirms “Buy” Rating for Cytokinetics (CYTK)
They currently have a $9.00 price target on the stock. Six other investment analysts have rated the stock with a buy rating, Cytokinetics has a consensus rating of “Buy” and a consensus target price of $10.73.
Breaking News!
Expo is re-tooling with 3D Printers, to mass produce dog houses!
My money is on a bounce! There was nothing to justify the 10% drop. Not sure what folks were expecting from the earnings, with 2 drugs continuing to advance through clinical trials. They have plenty of cash and expenses have been about what was expected. When it bounces, it will be quick!
See attached link. Not sure where you get your info, but I'm quite confident with mine.
http://tickerreport.com/banking-finance/488027/cytokinetics-given-buy-rating-at-zacks-cytk/?utm_source=ADVFN&utm_medium=banner&utm_campaign=ADVFN
This is ridiculously cheap! Get some at this price while you can!!!
"During the first quarter, Cytokinetics convened meetings with each of FDA and EMA to review results from BENEFIT-ALS and to discuss plans to advance tirasemtiv to the next stage of clinical development. Based on feedback from those meetings, Cytokinetics is preparing to initiate a large, international Phase III clinical trial of tirasemtiv in patients with ALS." stated Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "In addition, we are pleased that COSMIC-HF recently completed patient enrollment. We are readying for the availability of results from this clinical trial which are expected later this year and are preparing for the potential progression of omecamtiv mecarbil to Phase III in collaboration with Amgen."
I loaded up @ $5.56!!!
At the end of the quarter, the company has $117.5 million in cash, cash equivalents and investments.
Cytokinetics Given Buy Rating at Zacks
Posted by Stephan Byrd on Apr 30th, 2015
Cytokinetics (NASDAQ:CYTK)‘s stock had its “buy” rating reiterated by Zacks in a report released on Thursday. They currently have a $8.80 target price on the stock. Zacks‘s price objective would suggest a potential upside of 39.90% from the company’s current price.
Zacks’ analyst wrote, “CYTOKINETCS is a different kind of company. It is increasingly unusual that an emerging growth biotechnology company would be dedicated to the discovery, development and commercialization of therapeutics. Similarly, it is more and more uncommon for a biopharmaceutical company to tackle the pursuit of new treatments for multiple disease areas, including cancer and cardiovascular diseases. However, the most important distinguishing feature of Cytokinetics is instead found in our commitment to innovation that has translated our focus on the cytoskeleton into a Research and Development pipeline of multiple, first-in-class compounds. All of the programs we are pursuing offer entirely novel therapeutic approaches to severe unmet clinical needs. The reason is simple. Innovative therapeutics are much more likely to bring substantial benefits to patients. “
Separately, analysts at Piper Jaffray upgraded shares of Cytokinetics from a “neutral” rating to an “overweight” rating and set a $13.00 price target on the stock in a research note on Friday, February 13th. Six equities research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average price target of $10.80.
Woot! Woot!
All aboard the $0.02+ train!!! On our way back to Nickelville and beyond!
Woot! Woot!
All Aboard!!!!
Mattel CEO Promises 'Rapid Redo' as Sales Drop Continues
Mattel Inc.'s (MAT) new chief executive, Christopher Sinclair, pledged a "rapid redo" of the company culture to develop more creative toys and sell them better, after Mattel(MAT) posted its sixth straight quarter of sales declines.
Two weeks after getting the permanent CEO role, Mr. Sinclair offered broad plans to try to fix the world's largest toy maker. Those include working faster to develop toys, encouraging partnerships with technology companies, improving displays at retailers, and telling better stories around top brands like Barbie and Thomas the Tank Engine.
"The board and I don't want to waste time in moving forward with the necessary changes to revitalize the business," Mr. Sinclair said Thursday.
The assessment came as Mattel(MAT) posted another quarter of sales declines, largely due to the stronger dollar. Overall sales fell 2.5% to $922.7 million, with an 8% increase in North America that was offset by a 14% decline in its international division. The company reported a loss of $58.2 million, widening from a year-earlier loss of $11.2 million.
The stronger dollar dragged down results for long-struggling brands Barbie and Fisher-Price. Barbie sales fell 14%, the sixth straight double-digit decline, while Fisher-Price's fell 3%, its sixth straight decline.
Mattel (MAT) is trying to recover from a tough three-year stretch when the company's culture became bogged down by bureaucracy and what some saw as excessive meetings, while designers felt they weren't free to create innovative toys, The Wall Street Journal previously reported. After sales fell 5.6% last holiday season, Mattel(MAT) fired CEO Bryan Stockton, replacing him with Mr. Sinclair, a longtime board member.
Mattel (MAT) had been trying to rejuvenate its creative culture with the return of Richard Dickson, who at one point led Barbie's revival before leaving for a role at an apparel company. But his arrival last May came too late to salvage the holiday season.
Still, Mr. Dickson was promoted to chief operating officer earlier this month, an indication he is being tested for eventually taking the top job. He is working closely with Mr. Sinclair on the turnaround.
First-quarter results don't provide a good bellwether for the toy industry, as sales are heavily weighted toward the winter holiday season. Mattel(MAT) typically does around one-sixth of its sales during the first quarter.
Some brands posted better results in stores, due to less inventory left on shelves following the holidays than in the prior-year period. Barbie's retail sales rose double-digits in the U.S., while Fisher-Price's rose at a mid-single- digit rate globally in the first quarter.
The results, including a strong indication that Mattel's(MAT) generous dividend would be maintained, relieved investors. Mattel(MAT) shares rose nearly 6.5% in after-hours trading to $26.90. So far this year, Mattel(MAT) shares have lost 18%, making it one of the worst performers in the S&P 500.
Mattel (MAT) offered more signs that business isn't as usual. Mr. Dickson has been quick to seal partnerships with Google Inc. and other technology companies to modernize some of its older toys. Mattel(MAT) also on Thursday said it would partner with Quirky, a platform that links companies with inventors to develop new products.
There is urgency for Mattel(MAT) to act. Wells Fargo analyst Timothy Condor on Thursday wrote that if Mattel(MAT) doesn't lay out a clear turnaround plan or if it stumbles any more, it would be ripe for an activist to call for more upheaval.
Mattel and Quirky Partner to Help Reimagine PlayCompanies to collaborate connecting Quirky’s vibrant global inventor community with Mattel’s iconic brands and products ranging from toys and games to baby gear and preschool products.
EL SEGUNDO, Calif.--(BUSINESS WIRE)-- Mattel(MAT) and Quirky, the company that makes invention accessible, today announced an exclusive partnership to spark invention in toys, play and baby gear. Harnessing the power of Quirky’s global community and Mattel’s iconic Brands, Quirky and Mattel(MAT) will reimagine Mattel’s portfolio of products to drive growth for brands like Barbie, Fisher-Price, and Hot Wheels. This partnership combines Mattel’s scale and 70 years of toy-making history with Quirky’s open and agile approach to product development.
Starting today, the companies invite everyone to submit new product ideas for toys, games, and family products to Quirky’s online platform to support Mattel’s vision to create deeper consumer connections and reimagine how children play, learn, and grow. Quirky and Mattel(MAT) will begin developing the new products alongside Quirky’s global community, the first of which may be available for holiday 2015. Watch the video to learn more here.
“This marks a new era for Mattel,” said Richard Dickson, President and Chief Operating Officer, Mattel(MAT). “Leveraging Quirky’s platform allows us to discover new ideas for our toys and unique solutions for our baby products. Just as importantly, this new partnership will enable us to accelerate the speed and scope of invention by tapping into Quirky’s dynamic community. This is an industry about creating and inventing, whether based on a consumer insight or a really fun idea, with the power of our own talented inventors and now Quirky, we are realizing our vision to reimagine Mattel’s core brands and bring truly great unexpected play to families.”
The relationship with Mattel(MAT) is the third addition to the Powered by Quirky initiative, a new series of product-development partnerships with category leaders. Powered by Quirky enables Quirky’s community to work with industry-leading companies like Mattel(MAT) to impact the brands they love.
“Few companies inspire creative imagination like Mattel,” said Ben Kaufman, CEO and Founder, Quirky. “Partnering with Mattel(MAT) gives our community the opportunity to tap into their own childhood memories to dream up entirely new ways to play.”
To date, Quirky has received close to 15,000 toy-related idea submissions from its community. Starting today, each and every idea in the category will have an opportunity to become the next big product from Mattel(MAT).
China Wants To Put 3D Printers In Every Elementary School By Next Year!
Could Hannover House be a target of Alibaba?
Alibaba Pictures, a film studio acquired and renamed by Alibaba(BABA) last year, and which also trades in Hong Kong, said it is considering acquiring some entertainment-related businesses (http://blogs.wsj.com/ moneybeat/2015/04/08/action-on-alibaba-pictures/?mod=overheard&mod=overheard)from the parent company.
Big run on CYTK is coming! Better get in now, if you want to enjoy the run to $13!
South San Francisco, CA, April 8, 2015 - Cytokinetics, Incorporated
(Nasdaq: CYTK http://finance.yahoo.com/q?s=rnvs&d=t ) announced today
that Robert I. Blum, President and Chief Executive Officer, is scheduled
to present a corporate update at the 14(th) Annual Needham Healthcare
Conference on Wednesday, April 15, 2015 at 11:20 AM at the Westin New
York Grand Central in New York, NY.
Interested parties may access the live audio of this presentation by
visiting the Investor Relations section of the Cytokinetics website at
www.cytokinetics.com. The webcast replay of the presentation will be
archived on the Presentations page within the Investor Relations section
of Cytokinetics' website for two weeks following the completion of the
event.
Alibaba has it's eye on HHSE!
Alibaba proposes asset injection for ailing film arm
MARKETWATCH 8:33 AM ET 4/8/2015
BEIJING--Chinese e-commerce giant Alibaba Group Holding Ltd.(BABA) on Wednesday proposed an injection of assets into its unprofitable movie arm, sending shares in the entertainment business soaring.
Hong Kong-listed Alibaba Pictures Group Ltd. said that its parent, Alibaba Group(BABA) , proposed folding its online movie ticketing business and its movie production crowdfunding platform into the struggling Alibaba Pictures unit.
Alibaba Pictures' Hong Kong-traded shares , which were halted March 24, rose 36.7 % when they resumed trading on Wednesday, finishing at 3.91 Hong Kong dollars (50 U.S. cents).
Alibaba Pictures' announcement didn't specify the business units being discussed for the asset injection. However, a person familiar with the proposed transaction said the businesses are Alibaba's(BABA) Taobao Movie ticketing website and Yule Bao, a platform t hat allows Chinese investors to financially back movies. Both services were launched last year.
Alibaba Group (BABA) sees the integration of the businesses as a way to couple its strength in e-commerce and its user base of hundreds of millions of people with the production function of its filmmaking subsidiary, the person said. The proposed injection, if carried out, would create a new business model for filmmaking that traditional production companies in China lacked, the person said.
Woot! Woot!
All Aboard!
Next stop is .02+!!!
EXPH up 900%!
Dog houses must be in high demand!
Blue Earth Announces Sumter CHP Plant Energized on March 30, 2015
HENDERSON, NV -- (Marketwired) -- 04/01/15 -- Blue Earth, Inc.(BBLU) an alternative/renewable energy and energy efficiency services company, energized its initial combined heat and power ("CHP") energy plant at the Pilgrim's Pride Corporation's poultry processing facility in Sumter, South Carolina. Blue Earth owns and operates the $5.3 million energy plant. With combined heat and power (CHP) solutions, electricity is generated and the heat from the generator is captured and utilized for useful purposes, lowering energy costs, reducing greenhouse gas emissions and improving energy efficiency.
"We are extremely pleased that our initial CHP energy plant is energized at Sumter and that Blue Earth has become an Independent Power Producer or IPP," said President and COO Rob Potts. "The IPP model of long term recurring revenue received for Sumter from the host for hot water, scrubbed methane gas and the electrical power sold to the local utility introduces a third operating segment for the Company that is a major milestone and will contribute to our long term shareholder value."
CYTOKINETICS ANNOUNCES PUBLICATION OF RESULTS FROM PHASE II TRIAL OF TIRASEMTIV IN PATIENTS WITH MYASTHENIA GRAVIS
Data from Evidence of Effect Trial Provide Support for Novel Mechanism of Action in Neuromuscular Diseases
South San Francisco, CA - March 25, 2015
Cytokinetics, Incorporated (Nasdaq: CYTK) announced the publication of a manuscript relating to its fast skeletal muscle troponin activator tirasemtiv in the journal Neurotherapeutics. This publication summarizes results from a Phase IIa “Evidence of Effect” or hypothesis-generating clinical trial which evaluated tirasemtiv in patients with generalized myasthenia gravis (MG). Tirasemtiv is the lead drug candidate from Cytokinetics' skeletal muscle contractility program and is being developed as a potential treatment for amyotrophic lateral sclerosis (ALS).
“We are pleased to share additional clinical data relating to tirasemtiv in patients with generalized myasthenia gravis,” stated Andrew A. Wolff, MD, FACC, Cytokinetics’ Senior Vice President and Chief Medical Officer. “We believe that effects observed on the Quantitative Myasthenia Gravis score and on vital capacity following administration of a single dose of tirasemtiv support the evaluation of skeletal muscle activation in patients with neuromuscular disorders including ALS. We are preparing to initiate a Phase III clinical development program to evaluate the effects of tirasemtiv on measures of respiratory function and other measures of skeletal muscle performance in patients with ALS.”
The publication, titled “A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis,” appeared online in the March edition of the journal Neurotherapeutics. The primary objective of this early-stage clinical study was to evaluate the effects of single 250 mg and 500 mg doses of tirasemtiv versus placebo on measures of skeletal muscle function and fatigability in patients with generalized MG and persistent muscle weakness. The secondary objectives of the study were to evaluate and characterize the relationship, if any, between the doses and plasma concentrations of tirasemtiv and its pharmacodynamic effects, and to evaluate the safety and tolerability of tirasemtiv administered as single doses to patients with MG. The authors concluded that 6 hours after dosing, tirasemtiv produced dose-related improvements from baseline in the Quantitative MG (QMG) score (slope: –0.49 QMG point per 250 mg administered; p=0.02; lower scores indicate better function) and in percent predicted forced vital capacity (slope: 2.2 % increase per 250 mg administered; p=0.04). The QMG improved by >3 points in twice as many patients after 500 mg tirasemtiv than after placebo. Both doses of tirasemtiv were well tolerated; there were no premature terminations or serious adverse events. The results of this study suggest that tirasemtiv may improve muscle function in patients with MG and support further development of tirasemtiv in neuromuscular diseases.
Obama to sign order cutting U.S. gov't greenhouse gas emissions
WASHINGTON, March 19 (Reuters) - U.S. President Barack Obama will sign an executive order on Thursday that sets a goal for the U.S. government to cut its greenhouse gas emissions by 40 percent by 2025, the White House said on Thursday.
The federal government is the single largest energy consumer in the United States, the White House said in a statement. Meeting the goal would cut 21 million metric tons of greenhouse gas emissions from 2008 levels, it said.
Several large private-sector partners, including IBM(IBM) , General Electric(GE) and Honeywell(HON), also committed to cutting a combined 5 million metric tons.
Obama has made fighting climate change a top priority in his final two years in office. The White House sees it as critical to his legacy.
In November, Obama reached an agreement with Chinese President Xi Jinping that set a goal of reducing overall U.S. greenhouse gas emissions by 26 percent to 28 percent below 2005 levels by 2025. China agreed to begin lowering its carbon dioxide emissions by 2030, with the intention of trying to do so earlier.
White House senior adviser Brian Deese said the federal government's share of greenhouse gas emissions in the overall U.S. economy is "modest," but that the announcement is significant.
"The potential from this announcement, however, is significant both because we can drive substantial reductions across the entire federal footprint and because our efforts to do that leverage both innovation and investment in the private sector," Deese said on a call with reporters.
The Environmental Protection Agency last year offered a Clean Power Plan that set deadlines for states to submit proposals to meet power plant carbon emission reduction goals.
A dozen states, including Kentucky, West Virginia, Indiana and Wyoming, sued the EPA last August, soon after the plan was unveiled, saying its use of a certain section of the Clean Air Act was illegal. The federal D.C. Circuit Court of Appeals will hear the case on April 16.
Obama's budget proposal for fiscal 2015 released last month called for a 7 percent boost in funding for clean energy and a $4 billion fund to encourage U.S. states to make faster and deeper cuts to emissions from power plants. It also called for the permanent extension of tax credits used by the wind and solar power industries. (Additional reporting by Valerie Volcovici; Editing by Peter Cooney and Jeffrey Benkoe)
JACKSONVILLE, FL, and HENDERSON, NV -- (Marketwired) -- 03/19/15 -- Stellar Energy was selected by Blue Earth, Inc.(BBLU), the renewable/alternative energy and energy efficiency services company, to design and supply a combined heat and power (CHP) plant. The CHP plant is at the Pilgrim's Pride Corporation poultry processing facility located in Sumter, South Carolina and is currently in the commissioning process and scheduled to turn on March 30, 2015. Blue Earth will own and operate the $5.3 million energy plant.
This will be the 1st big step!
JACKSONVILLE, FL, and HENDERSON, NV -- (Marketwired) -- 03/19/15 -- Stellar Energy was selected by Blue Earth, Inc.(BBLU), the renewable/alternative energy and energy efficiency services company, to design and supply a combined heat and power (CHP) plant. The CHP plant is at the Pilgrim's Pride Corporation poultry processing facility located in Sumter, South Carolina and is currently in the commissioning process and scheduled to turn on March 30, 2015. Blue Earth will own and operate the $5.3 million energy plant.
This will be the 1st big step!
CYTOKINETICS ANNOUNCES COMPLETION OF ENROLLMENT IN COSMIC-HF
Results Expected Later This Year to Inform Potential Progression of Omecamtiv Mecarbil to Phase III
South San Francisco, CA - March 13, 2015
Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure) has completed enrollment of the approximately 450 patients planned in the expansion phase of the clinical trial. In addition, the company announced that over 200 patients have completed the protocol-specified 20-week duration of dosing in this phase of the trial and reaffirmed that results from COSMIC-HF are expected to be available in the second half of 2015. COSMIC-HF is being conducted by Amgen in collaboration with Cytokinetics.
“We are pleased to reach this milestone in the development program for omecamtiv mecarbil,” stated Fady I. Malik, M.D., Ph.D., Cytokinetics' Senior Vice President, Research and Development. “COSMIC-HF will provide important information that will inform the potential progression of omecamtiv mecarbil to Phase III. We look forward to data from COSMIC-HF later this year and continue to prepare with Amgen for the initiation of a potential Phase III registration program.”
Omecamtiv mecarbil is the company’s lead drug candidate from its cardiac muscle contractility program. Amgen holds an exclusive, worldwide license to omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization rights. Additional information on COSMIC-HF and other completed Phase II clinical trials of omecamtiv mecarbil can be found at www.clinicaltrials.gov.
COSMIC-HF: Phase II Clinical Trial of Oral Omecamtiv Mecarbil in Patients with Heart Failure
COSMIC-HF is a double-blind, randomized, placebo-controlled, multicenter, study with two parts, a dose escalation phase and an expansion phase. The dose escalation phase assessed the pharmacokinetics and tolerability of three oral modified-release formulations of omecamtiv mecarbil in patients with heart failure and left ventricular systolic dysfunction and was used to select one formulation for further evaluation. During the dose escalation phase approximately 40 patients were randomized1:1:1:1 to placebo or one of three different oral formulations of omecamtiv mecarbil in each of two ASCENDING dose escalation cohorts. The dose of omecamtiv mecarbil was 25 mg twice daily in the first escalation cohort and 50 mg twice daily in the second escalation cohort. The dose escalation phase of COSMIC-HF completed in 2013 and informed progression to the expansion phase.
The ongoing expansion phase of the trial has enrolled approximately 450 patients randomized 1:1:1 to receive placebo, 25 mg, or 50 mg twice daily of omecamtiv mecarbil. Escalation to the 50 mg dose depends on the plasma concentration of omecamtiv mecarbil following 2 weeks of dosing with 25 mg twice daily. The primary objective of the expansion phase of COSMIC-HF is to characterize the safety, tolerability, and pharmacokinetics of oral omecamtiv mecarbil during 20 weeks of treatment. Secondary objectives are to assess changes from baseline in systolic ejection time, stroke volume, left ventricular end-systolic diameter, left ventricular end-diastolic diameter, heart rate and N-terminal pro-brain natriuretic peptide (a biomarker associated with the severity of heart failure) during 20 weeks of treatment.
About Omecamtiv Mecarbil
Omecamtiv mecarbil is a novel cardiac myosin activator and is the subject of a collaboration between Cytokinetics and Amgen. Cardiac myosin is the cytoskeletal motor protein in the cardiac muscle cell that is directly responsible for converting chemical energy into the mechanical force resulting in cardiac contraction. Cardiac contractility is driven by the cardiac sarcomere, a highly ordered cytoskeletal structure composed of cardiac myosin, actin and a set of regulatory proteins, which is the fundamental unit of muscle contraction in the heart. Cardiac myosin activators have been shown preclinically to work in the absence of changes in intracellular calcium in cardiac myocytes by a novel mechanism that directly stimulates the activity of the cardiac myosin motor protein. Cardiac myosin activators appear to accelerate the rate-limiting step of the myosin enzymatic cycle and shift the enzymatic cycle in favor of the force-producing state. Preclinical research has shown that this mechanism does not increase the velocity of cardiac contraction, but instead, increases the systolic ejection time, resulting in an increase in cardiac contractility and cardiac function in a potentially more oxygen-efficient manner.
About Heart Failure
Heart failure is a debilitating syndrome affecting over 5 million people in the United States. Over 3 million patients are hospitalized each year with a primary or secondary diagnosis of heart failure in the United States. Heart failure is among the most common causes of hospitalization in patients over 65 years of age and is the leading cause of rehospitalization in Medicare beneficiaries. Despite available therapies, readmission rates for patients remain high within one year of hospital discharge and mortality rates exceed 50% over the five-year period following a diagnosis of heart failure. The prevalence of heart failure is increasing with the aging population and the increased likelihood of survival following acute myocardial infarction. The limited effectiveness of current therapies points to the urgent need for next-generation therapeutics.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics is developing tirasemtiv, a fast skeletal muscle activator, as a potential treatment for amyotrophic lateral sclerosis (ALS). Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights. All of these drug candidates have arisen from Cytokinetics' muscle biology focused research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at http://www.cytokinetics.com/.
Blue Earth Reports Fourth Quarter and Full Year 2014 Results
HENDERSON, NV -- (Marketwired) -- 03/16/15 -- Blue Earth, Inc. (NASDAQ: BBLU) an alternative/ renewable energy and energy efficiency services company, announced financial results for the fourth quarter and full year ended December 31, 2014.
As detailed below, the Company announced strong growth in revenues for both the fourth quarter of 2014 and the full year 2014 in both the Energy Efficiency & Technology and Construction divisions. Gross profits for the company, however, were down for both the fourth quarter and full year, with the bulk of the decline attributable to operating losses in the Construction division caused by project losses on legacy business in Hawaii.
Total consolidated revenue for the fourth quarter of 2014 was $8,787,790, an increase of $5,448,263 or 163.1%, when compared with consolidated revenue of $3,339,527 for the fourth quarter of 2013. The current revenues represent sales from the Company's operating segments, Energy Efficiency & Technology ($1,422,923) and Construction ($7,364,867) as compared to fourth quarter sales of ($1,144,410) from Energy Efficiency & Technology and ($2,195,117) from Construction in 2013.
For the full year ended December 31, 2014 revenues were $18,260, 758, an increase of $7,955,022 or 77.2%, when compared with consolidated revenue of $10,305,736 in 2013.
The full year revenues represent sales from the Company's operating segments, Energy Efficiency & Technology ($6,694,166) and ($11,566,592) from Construction in 2014 as compared to Energy Efficiency and Technology ($3,648,908) and Construction ($6,656,828) in 2013.
Energy Efficiency & Technology sales include energy efficiency retrofits through Keep Your Cool® programs, website sales, refrigeration/HVAC services and the UPStealth® battery backup management systems. Construction sales are from installation of alternative/renewable energy systems and installation and maintenance of HVAC systems. Energy Efficiency & Technology's revenues were positively impacted by a new contract with a national chain of convenience stores, increased website sales, and increased sales of UPStealth® battery backup management systems.
Total consolidated gross profit for the fourth quarter of 2014 was $593,008 or 6.7% of revenues, compared to $405,963 or 12.2% of revenues for the fourth quarter of 2013. Energy Efficiency & Technology had a gross profit of $746,937 or 52.5% compared to a gross loss of ($153,929) or (2.1%) for Construction. By comparison in the fourth quarter of 2013, Energy Efficiency & Technology had a gross profit of $513,288 or 44.9% compared to a gross loss of ($107,325) or (4.9%) for Construction. Construction division gross losses for the quarter was the result of losses incurred on the sale of solar panels held in inventory, cost overruns on a project in Hawaii and lower margins for a project under construction in mainland US. Solar panels in inventory were sold after the manufacturer of the panels withdrew from the U.S. market, making the panels unacceptable for our projects.
Total consolidated gross profit for the full year of 2014 was $4,175,220 or 22.9% of revenues, compared to $3,139,272 or 30.5% of revenues for 2013. Energy Efficiency & Technology had a gross profit of $3,934,437 or 58.8% compared to $240,783 or 2.1% for Construction. By comparison in the full year of 2013, Energy Efficiency & Technology had a gross profit of $1,828,288 or 54.3% compared to $1,122,074 or 16.9% for Construction. Construction division gross profits were lower in 2014 because of a loss on the sale of a project in Hawaii in addition to the factors cited in the fourth quarter discussion.
Total consolidated operating expenses for the fourth quarter of 2014 were $9,671,880, compared to $13,460,173 for the fourth quarter of 2013 decrease of $3,788,293 or (28.1%).
Total consolidated operating expenses for the full year of 2014 were $31,109,358, compared to $28,497,962 for the full year of 2013 an increase of $2,611,396 or 9.2%.
Net loss for the fourth quarter of 2014, was $9,373,682 as compared to a net loss of $13,187,926 for the fourth quarter of 2013, a decrease of $3,814,244. Excluding the non-cash expenses of common stock for services, amortization of intangible assets acquired for stock and stock options/warrants issued for services, the loss would have been $5,145,214 and $2,938,227 for the fourth quarter of 2014 and 2013, respectively. The increase is attributable primarily to losses and decreased margins in the Construction segment.
Net loss for the full year of 2014, was $27,614,459 as compared to a net loss of $25, 473,394 for the full year of 2013, an increase of $2,141,065. Excluding the non-cash expenses of common stock for services, amortization of intangible assets acquired for stock and stock options/warrants issued for services, the loss would have been $15,857,201 and $5,748,924 for the full year of 2014 and 2013, respectively. The increase is attributable primarily to increased overhead costs associated with expanding the business.
The net loss attributed to common shareholders was $9,373,682 in the fourth quarter 2014 compared to $14,320,562 in the fourth quarter of 2013. The net loss translates to ($0.10) per basic and diluted share for the fourth quarter of 2014 as compared to a net loss of ($0.29) per basic and diluted share in the fourth quarter of 2013.
The net loss attributed to common shareholders was $29,118,041 in the full year 2014 compared to $28,661,844 in the full year of 2013 after taking into account preferred dividends of $1,503,582 and $3,188,450 in 2014 and 2013 respectively. The net loss translates to ($0.40) per basic and diluted share for the full year of 2014 as compared to a net loss of ($0.79) per basic and diluted share in the full year of 2013.
"Results for the fourth quarter improved over the previous three quarters of 2014 as revenues increased. Gross margins and profits on the Construction business suffered from the effects of the first three quarters, but we believe the negative margins are behind us due to a more focused business with the current profitable projects. Full year revenues were up significantly year on year but the reduced margins in the Construction segment produced results that were below our expectations for the year. We believe that the legacy problems in the Construction segment are now behind us and expect improved results in 2015," stated Brett Woodard, CFO of Blue Earth, Inc.
1,500,001 shares traded and up 50% @ 0.0003!
Oil for stock!!!
Total revenue was $3.4 million in 2014, compared to $1.6 million in 2013.
http://investors.secondsight.com/releasedetail.cfm?ReleaseID=901145
The replay can be accessed by dialing (800) 633-8284 (U.S.) or (402) 977-9140 (International). The conference ID for the replay is 21763065.
Have fun in that line of 1! Technically, that's not a line!
The call is @ 4:30 ET today!
Tomorrow should be a wild opening bell. Better get shares while they are cheap today! I just loaded up @ 16.
Superman is back and still our full time CEO!!!!
LMFAO
Woot! Woot!
All Aboard!!!
Next stop +.02 Land!!!!
Time to load up!